Whalesbook
Conflict's Impact on India's Pharma Sector
The ongoing conflict involving Iran, Israel, and the United States is putting pressure on India's pharmaceutical sector, affecting medicine prices and supply. Traders at major wholesale markets report that rising input costs are already impacting the supply chain. This situation highlights the sector's vulnerability to global disruptions, especially given its reliance on imported raw materials for drug manufacturing.
Rising Packaging Costs Squeeze Medicine Prices
A main reason for higher medicine costs is the rising price of essential packaging materials like aluminium and plastic. Global disruptions, especially in shipping and energy markets, have driven up these commodity prices. Aluminium costs have climbed due to geopolitical risks and supply chain issues. These higher packaging expenses directly increase overall pharmaceutical production costs, affecting medicine affordability.
Common Medicines Face Price Hikes, Supply Risks
Concerns over price and availability extend beyond specialized drugs. Common medications for widespread ailments—such as Paracetamol for fever, Amoxicillin for infections, Metformin for diabetes, and Azithromycin for respiratory illnesses—are now expected to face pricing adjustments and supply challenges. These drugs are vital for daily healthcare for millions in India, highlighting the public health impact of these supply chain weaknesses. Although current stocks are sufficient, industry groups warn that the full effects could become clearer in coming weeks if global tensions continue.
India Pursues Pharma Self-Reliance
To counter such disruptions, India is actively working towards greater self-reliance in its pharmaceutical supply chain. The government's Production Linked Incentive (PLI) schemes, launched in 2020, aim to boost domestic manufacturing of Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and drug intermediates. This reduces reliance on imports, mainly from China. India's API exports surpassing imports in FY24-25 marks progress. Industry figures note that over 70% of India's API needs are imported, with China as the main supplier. Current geopolitical events highlight the urgency of these efforts to build resilience against external shocks and secure medicine supplies.
Persistent Supply Chain Weaknesses
Despite progress toward self-sufficiency, India's pharmaceutical sector is still vulnerable to global geopolitical and economic shifts. Heavy reliance on imported packaging materials, subject to price swings and shipping delays, remains a key weakness. While PLI schemes target APIs, the supply chain for other critical inputs like specialized chemicals and packaging components, affected by global energy and metal markets, also needs strategic focus. Companies relying on fewer suppliers for these inputs face higher risks of margin squeeze and supply interruptions, especially for low-margin generic drugs. Past events, like COVID-19 export bans, show how government actions to secure domestic supply can have global effects. The sector's strength in generic manufacturing is challenged by these external supply chain risks and the need for continued investment in all input areas.
Boosting Supply Chain Resilience
Looking ahead, India's pharmaceutical industry must balance global competitiveness with strengthening its supply chains against geopolitical and economic uncertainties. While analysts generally predict continued export growth, the current geopolitical situation adds execution risks that could slow near-term performance. Ongoing efforts to diversify sourcing and increase domestic manufacturing are key to navigating future disruptions and ensuring essential medicines remain available and affordable.